Relevance of prostate cancer in patients with synchronous invasive bladder urothelial carcinoma: A monocentric retrospective analysis - Abstract

OBJECTIVES: We retrospectively reviewed data of patients with incidental prostate cancer (PCa) who underwent radical cystoprostatectomy (RCP) for invasive bladder cancer and we analyzed their features with regard to incidence, pathologic characteristics, clinical significance, and implications for management.

MATERIAL AND METHODS: Clinical data and pathological features of 64 patients who underwent standard RCP for bladder cancer were included in this study. Besides the urothelial carcinoma of the urinary bladder, the location and tumor volume of the PCa, prostate apex involvement, Gleason score, pathological staging and surgical margins were evaluated. Clinically significant PCa was defined as a tumor with a Gleason 4 or 5 pattern, stage ≥ pT3, lymph node involvement, positive surgical margin or multifocality of three or more lesions. Postoperative follow-up was scheduled every 3 months in the first year, every 6 months in the second and third year, annually thereafter.

RESULTS: 11 out of 64 patients (17.2%) who underwent RCP had incidentally diagnosed PCa. 3 cases (27.3%) were diagnosed as significant PCa, while 8 cases (72.7%) were clinically insignificant. The positive surgical margin of PCa was detected in 1 patient with significant disease. The prostate apex involvement was present in 1 patient of the significant PCa group. Median follow-up period was 47.8 ± 29.2 (range 4-79). During the follow-up, biochemical recurrence occurred in 1 patient (9%). Concerning the cancer specific survival there was no statistical significance (P = 0.326) between the clinically significant and clinical insignificant cancer group.

CONCLUSIONS: In line with published studies, incidental PCa does not impact on the prognosis of bladder cancer of patients undergoing RCP.

Written by:
Dell'Atti L.   Are you the author?
Department of Urology, University Hospital "S. Anna", Ferrara.  

Reference: Arch Ital Urol Androl. 2015 Mar 31;87(1):76-9.
doi: 10.4081/aiua.2015.1.76

PubMed Abstract
PMID: 25847902 Prostate Cancer Section